175 related articles for article (PubMed ID: 29860455)
21. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
Veritti D; Sarao V; Lanzetta P
J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
[TBL] [Abstract][Full Text] [Related]
22. Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes.
Campa C; Kasman I; Ye W; Lee WP; Fuh G; Ferrara N
Invest Ophthalmol Vis Sci; 2008 Mar; 49(3):1178-83. PubMed ID: 18326747
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab revisited: its use in different mouse models of ocular pathologies.
Hollanders K; Van Bergen T; Van de Velde S; Sijnave D; Vandewalle E; Moons L; Stalmans I
Curr Eye Res; 2015 May; 40(6):611-21. PubMed ID: 25117905
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
[TBL] [Abstract][Full Text] [Related]
26. Successful single treatment with ziv-aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model.
Gore A; Horwitz V; Cohen M; Gutman H; Cohen L; Gez R; Kadar T; Dachir S
Exp Eye Res; 2018 Jun; 171():183-191. PubMed ID: 29548928
[TBL] [Abstract][Full Text] [Related]
27. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
28. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
Lazic R; Gabric N
Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
[TBL] [Abstract][Full Text] [Related]
29. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL
Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia.
Rhéaume MA; Sebag M
Can J Ophthalmol; 2008 Oct; 43(5):576-80. PubMed ID: 18982035
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Subconjunctival Aflibercept Versus Bevacizumab for Prevention of Corneal Neovascularization in a Rat Model.
Gal-Or O; Livny E; Sella R; Nisgav Y; Weinberger D; Livnat T; Bahar I
Cornea; 2016 Jul; 35(7):991-6. PubMed ID: 27124775
[TBL] [Abstract][Full Text] [Related]
33. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.
Chabot S; Jabrane-Ferrat N; Bigot K; Tabiasco J; Provost A; Golzio M; Noman MZ; Giustiniani J; Bellard E; Brayer S; Aguerre-Girr M; Meggetto F; Giuriato S; Malecaze F; Galiacy S; Jaïs JP; Chose O; Kadouche J; Chouaib S; Teissié J; Abitbol M; Bensussan A; Le Bouteiller P
J Exp Med; 2011 May; 208(5):973-86. PubMed ID: 21482699
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal Bevacizumab for Choroidal Neovascularization Associated with Angioid Streaks: Long-term Results.
Lekha T; Prasad HN; Sarwate RN; Patel M; Karthikeyan S
Middle East Afr J Ophthalmol; 2017; 24(3):136-142. PubMed ID: 29279654
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.
Fine HF; Zhitomirsky I; Freund KB; Barile GR; Shirkey BL; Samson CM; Yannuzzi LA
Retina; 2009 Jan; 29(1):8-12. PubMed ID: 18784620
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J
Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751
[TBL] [Abstract][Full Text] [Related]
37. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
Augustin AJ; Puls S; Offermann I
Retina; 2007 Feb; 27(2):133-40. PubMed ID: 17290193
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks: a long-term follow-up study.
Rosina C; Romano M; Cigada M; de Polo L; Staurenghi G; Bottoni F
Eur J Ophthalmol; 2015; 25(1):47-50. PubMed ID: 25044143
[TBL] [Abstract][Full Text] [Related]
39. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
40. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
Ladewig MS; Karl SE; Hamelmann V; Helb HM; Scholl HP; Holz FG; Eter N
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
